Back to Search

A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)

  • Protocol Number: 201809141
  • Principal Investigator: Vij, Ravi
  • Cancer Types: Gene & Cellular Immunotherapy

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions